首页> 外文期刊>Knee surgery, sports traumatology, arthroscopy: official journal of the ESSKA >Mid- to long-term results of allograft-prosthesis composite reconstruction after removal of a distal femoral malignant tumor are comparable to those of the proximal tibia
【24h】

Mid- to long-term results of allograft-prosthesis composite reconstruction after removal of a distal femoral malignant tumor are comparable to those of the proximal tibia

机译:移除远端股骨恶性肿瘤后同种异体移植假体复合重建的中期长期结果与近端胫骨相媲美

获取原文
获取原文并翻译 | 示例
           

摘要

PurposeTo compare the outcomes of allograft-prosthesis composite for reconstruction after malignant tumors at the distal femur and proximal tibia.MethodsCase-control study of 24 patients with distal femur tumor and 21 with proximal tibia tumor. Union of the allograft-host interface was assessed by the International Society of Limb Salvage criteria, and complications according Henderson. Functional outcome was evaluated by the Musculoskeletal Tumor Society (MSTS) score, Western Ontario and McMaster Universities (WOMAC) score, and pain by a visual analog scale.ResultsThe median follow-up in the femoral group was 11.4 (range 2.3-25.0) years, and 10.1 (range 2.2-25.0) in tibial group. Incorporation of the allograft was successful in more than 90% in both groups. Tumor location was not significant predictor for allograft failure in multivariate analysis. Aseptic prosthesis loosening occurred in two patients in either group, and another patient in the tibial group had a breakage of the tibial insert. Excluding local recurrences and amputations, the prosthesis survival at 10years was 94.1% in the femoral group, and 83.3% in the tibial group (n.s.). For the patients with preserved limb, the median MSTS score was 23.6 in the femoral group and 22.8 in tibial group (n.s.). Likewise, there were no significant differences in median WOMAC score (n.s.) or VAS pain (n.s.).ConclusionsAllograft-prosthesis composite is an effective procedure for distal femur tumors related to the graft, prosthesis survival, and functional outcomes. The results are comparable to those for proximal tibial tumors.Level of evidenceTherapeutic study, Level III.
机译:Purposeto在远端股骨和近端胫骨上的恶性肿瘤后重建的同种异体移植假体复合材料的结果..患有24例股骨肿瘤和近端胫骨肿瘤的24例患者的方法控制研究。通过国际肢体救助标准和亨德森的并发症评估了同种异体移植界面的联盟。肌肉骨骼肿瘤会(MSTS)得分评估功能结果,西部安大略省和麦克马斯大学(Womac)得分,以及视觉模拟量表的疼痛。股骨组中的中位后续时间为11.4(2.3-25.0)年在胫骨组中,10.1(范围2.2-25.0)。同种异体移植的掺入在两组中成功超过90%。多元分析中同种异体移植失败的肿瘤位置不是显着的预测因子。在两组患者中发生无菌假体松动,并且胫骨组中的另一种患者突破胫骨插入物。不包括局部复发和截肢,第10年的假体存活率在股骨组中为94.1%,胫骨组(N.S.)中的83.3%。对于肢体保存的患者,股骨基团中位数MSTS评分为23.6分,胫骨基团(N.)中的22.8。同样,中位数Womac评分(N.S.)或VAS疼痛(N.S.)没有显着差异。结论AlloGrofer - 假体复合材料是与移植物,假体存活和功能结果相关的远端股骨肿瘤的有效方法。结果与近端胫骨肿瘤的结果相当。EVIVESTHERESTEMUTIC研究,III水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号